SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001694665-22-000113
Filing Date
2022-07-01
Accepted
2022-07-01 06:58:50
Documents
13
Period of Report
2022-07-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K evlo-20220701.htm   iXBRL 8-K 37875
2 EX-1.1 atmsalesagreementconformed.htm EX-1.1 297105
  Complete submission text file 0001694665-22-000113.txt   530776

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evlo-20220701.xsd EX-101.SCH 1903
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evlo-20220701_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evlo-20220701_pre.xml EX-101.PRE 13047
7 EXTRACTED XBRL INSTANCE DOCUMENT evlo-20220701_htm.xml XML 11252
Mailing Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139
Business Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139 781 479 2974
Evelo Biosciences, Inc. (Filer) CIK: 0001694665 (see all company filings)

IRS No.: 465594527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38473 | Film No.: 221059589
SIC: 2834 Pharmaceutical Preparations